Overexpression of Sirtuin-1 is associated with poor clinical outcome in esophageal squamous cell carcinoma

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SIRT1 expression is associated with poor prognosis of lung adenocarcinoma

(2015) Chong Li et al.   OncoTargets and Therapy

SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer

(2014) Akira Noguchi et al.   Cancer Medicine

Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption

(2013) Nirmala Pandeya et al.   Cancer Epidemiology

SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC

(2013) Tao Zhang et al.   PLoS One

SIRT1 inhibits proliferation of pancreatic cancer cells expressing pancreatic adenocarcinoma up-regulated factor (PAUF), a novel oncogene, by suppression of β-catenin

(2012) Il-Rae Cho et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

SIRT1, Is It a Tumor Promoter or Tumor Suppressor?

(2012) Chu-Xia Deng   International Journal of Biological Sciences

Aberrant Cytoplasm Localization and Protein Stability of SIRT1 is Regulated by PI3K/IGF-1R Signaling in Human Cancer Cells

(2012) Vanessa Byles et al.   International Journal of Biological Sciences

SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling

(2012) Guoan Xiang   ONCOLOGY REPORTS

Effects of Niacin Restriction on Sirtuin and PARP Responses to Photodamage in Human Skin

(2012) Claudia A. Benavente et al.   PLoS One

Sirtuins and Disease: The Road Ahead

(2012) Vincenzo Carafa et al.   Frontiers in Pharmacology

Transcription factor FOXL2 protects granulosa cells from stress and delays cell cycle: role of its regulation by the SIRT1 deacetylase

(2011) Bérénice A. Benayoun et al.   HUMAN MOLECULAR GENETICS

Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma

(2010) Ho Lee et al.   HUMAN PATHOLOGY

Amurensin G, a Potent Natural SIRT1 Inhibitor, Rescues Doxorubicin Responsiveness via Down-Regulation of Multidrug Resistance 1

(2010) W. K. Oh et al.   MOLECULAR PHARMACOLOGY

The Critical Role of the Class III Histone Deacetylase SIRT1 in Cancer

(2009) T. Liu et al.   CANCER RESEARCH

Sirtuin inhibitors

(2009) Francisco J Alcaín et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

(2008) Sonia Lain et al.   CANCER CELL

Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice

(2008) Rui-Hong Wang et al.   CANCER CELL

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis

(2008) Rui-Hong Wang et al.   MOLECULAR CELL

Sirtuins — novel therapeutic targets to treat age-associated diseases

(2008) Siva Lavu et al.   NATURE REVIEWS DRUG DISCOVERY

The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth

(2008) Ron Firestein et al.   PLoS One